Medicare Coverage Significantly Expanded for the Eversense E3 CGM System

By Business Wire On Feb 13, 2024

The decision is further recognition of Eversense as an important option for people with diabetes

Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc., a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).

“We welcome this policy change and look forward to bringing this differentiated CGM option to millions of more Americans through Medicare”

Medicare coverage has been expanded for implantable CGMs to include all people with diabetes using insulin, removing the previous requirement for multiple insulin administrations per day. The new policy has also been updated to cover non-insulin-users who have a history of problematic hypoglycemia. Noridian, Palmetto and National Government Services (NGS) are the first three MACs to publish final local coverage determinations (LCD). The earliest MAC expansion becomes effective on February 25, 2024 and the companies expect the remaining MACs to finalize their expansion in the near future.

“We welcome this policy change and look forward to bringing this differentiated CGM option to millions of more Americans through Medicare,” said Rudy Thoms, VP, CGM Commercial US of Ascensia Diabetes Care, a subsidiary of PHC Holdings Corporation. “Eversense E3 is a truly unique technology and optionality is key in diabetes care, where what works for one person does not always work for all. In particular, our Medicare users love that this twice-yearly CGM offers them unparalleled reliability and flexibility, without the burden of regular self-insertions and the constant reordering of supplies. It is important that people with diabetes have the same access to the benefits of a fully implantable, long-term CGM, as they do to traditional CGMs [that have a much shorter lifespan], and so we are thrilled to see this expansion.”

Recommended AI Interview: McAfee at CES 2024: Deepfake Audio Detection Technology using AI

Designed by Senseonics and brought to people by Ascensia, the Eversense E3 CGM System offers people a fully implantable option that is highly-differentiated from traditional CGMs:

The longest lasting CGM available, with up to 6-month sensor wear duration and two sensor insertion and removal procedures per year
Exceptional accuracy, with a mean absolute relative difference (MARD) of 8.5%^* demonstrated in the PROMISE Study¹ for the duration of sensor wear
The only CGM with a removable transmitter which can be taken on and off without wasting a sensor or adding a warm up period^†
The only CGM with predictive on-body alerts to never miss a critical event, especially at night while sleeping or when away from your phone.

Recommended AI Interview: The Future of Manufacturing: Industrial Generative AI and Digital Twins

[To share your insights with us as part of editorial or sponsored content, please write to sghosh@martechseries.com]